![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Generics Program Resumes In-Person Meetings
FDA Generics Program Resumes In-Person Meetings
The FDA announced yesterday that its generic drug program has resumed in-person, face-to-face meetings with industry, in a phased-in approach alongside videoconference meetings.
Initially, the option will only be available for pre-abbreviated new drug application (ANDA) product development meetings and pre-submission meetings, the agency said.
The availability of meetings “may be limited by facility capacity and logistical considerations,” the agency said.
The plan is to include “only core participants with a primary speaking role in-person while others will join virtually.”
Requests for in-person face-to-face meetings must be part of an initial meeting request package received on or after March 27, the agency said.
Upcoming Events
-
21Oct